These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17591994)

  • 1. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview.
    Dowling TC
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S3-7; quiz S23-5. PubMed ID: 17591994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits.
    Gilmartin C
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S15-22; quiz S23-5. PubMed ID: 17591991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.
    Papatheofanis F; Bookhart BK; Muser E; Piech CT
    J Occup Environ Med; 2008 May; 50(5):584-9. PubMed ID: 18469628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
    Kimel M; Leidy NK; Mannix S; Dixon J
    Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
    Lefebvre P; Duh MS; Mody SH; Bookhart B; Piech CT
    Dis Manag; 2007 Feb; 10(1):37-45. PubMed ID: 17309363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia management and chronic renal failure progression.
    Rossert J; Froissart M; Jacquot C
    Kidney Int Suppl; 2005 Dec; (99):S76-81. PubMed ID: 16336582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly.
    Agarwal AK
    J Am Med Dir Assoc; 2006 Nov; 7(9 Suppl):S7-S12; quiz S17-21. PubMed ID: 17098634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and costs associated with anemic chronic kidney disease patients.
    Rasu RS; Crawford T; Manley H; Balkrishnan R
    Curr Med Res Opin; 2008 Jan; 24(1):129-37. PubMed ID: 18034919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV; Robinson K; Singh AK
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B; Mariusz S; Jacek R
    Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
    Bieber E
    J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.